Pathophysiology
Role of MR Overactivation in CKD Progression
Role of MR Overactivation in CKD Progression
CKD progression in patients with T2D is multifactorial. Under certain conditions, the mineralocorticoid receptor (MR), switches its role from homeostatic regulator to pathophysiologic mediator, which is thought to contribute to inflammation and fibrosis in the kidneys and cardiovascular system.
Watch this video to find out more about the role of MR overactivation in CKD associated with T2D.
What factors lead to MR overactivation, and as a result, elevate risk of CKD progression and cardiovascular events?
Keep Exploring
You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.
This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.
